Infertility Clinical Trial
Official title:
Efficacy and Safety of R-hLH (Luveris ®) Priming Prior to R-HFSH Treatment in Infertile Women Undergoing IVF-ET
In programmes of IVF, normal women undergo controlled ovarian stimulation using exogenous
FSH injections to obtain multiple eggs. The process results in eggs of mixed quality with a
broad range of developmental and implantation potential.
The aim of the study was to determine whether, treatment with recombinant human LH prior to
the FSH injections can improve outcome for women undergoing IVF. High grade embryos implant
with a higher frequency and baby delivery rate than poor quality embryos. The mature oocyte
is the most important determinant of embryo quality. Early follicles, containing immature
eggs, have LH receptors in the theca cells that surround the follicle, and LH stimulates
these cells to produce factors essential for normal follicular development.
The intent of the study was to use recLH treatment prior to recFSH to treat a cohort of
follicles, so that they can all mature together, thus increasing the proportion of high
grade oocytes and their subsequent embryos
Normal women undergoing IVF (Total n = 146; GRI n = 43) were recruited in 4 centres in 3
countries, and all were started on treatment with a depo GnRH-agonist to suppress endogenous
gonadotropin secretion. Block randomisation lead to a distribution 71 untreated cases and 75
cases treated with rec-hLH (Luveris,[Serono]; 300IU/d) for 7 days. On the following days
recombinant follicle stimulating hormone (rec-hFSH) stimulation of the ovaries was initiated
using Gonal-f (150IU/d) for approximately 12 days.
HCG (3500IU) was given when >2 mature follicles were seen by ovarian ultrasound, and oocytes
(eggs) were fertilized in vitro after collection between 36 and 38h after the injection.
Embryos were scored for quality, and a maximum of 2 embryos were transferred 2 or 3 days
later.
Results During Luveris treatment the LH concentration was increased by approximately 3 IU/L,
but there was no change in the hormone profiles of androgens or estrogens in blood samples
measured in a central laboratory. Both groups of patients showed an increase in the
circulating anti-mullerian hormone, although there was no difference between the groups.
The Luveris treated group showed a significant (p=0.007) increase in the number of small
antral follicles, but to a degree that was not different from the control group.
During rec-hFSH stimulation, there was no difference in the duration of FSH injections
required or the total dose, or the total number of follicles seen, or the hormone profiles
observed.
The Luveris pre-treated group showed a slight (not significant) increase in oocyte yield. In
this group there was a significant increase in the normally fertilized embryo yield (no
treatment mean = 5.1; Luveris treatment mean = 7.0: p= 0.038).
Discussion The observations of negligible effects of LH upon the hormone profiles may be
explained by the fact that the hormone concetrations were at the lower limit of sensitivity
of the assay methods, and they do not preclude an effect within the follicles. We did
observe effects upon follicular development in the ultrasound profiles. Effects upon hormone
profiles may require both hormones (LH and FSH) to be present at the same time (instead of
in sequence).
The small effect of the pre-treatment upon normal embryo yield may be an important
observation.
Conclusion These results demonstrate that treating follicles with LH prior to FSH, may lead
to the development of more viable follicles than with FSH treatment alone. This should lead
to improved regimes of ovarian stimulation and improve the outcome potential for women
undergoing IVF.
Future Research Exploration of this phenomenon will be required in order to maximise any
potential benefit from the process. There are numerous sub-groups of patients who may
possibly benefit, including poor responding patients, but further data are required.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A |